Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
693.50
-1.49 (-0.21%)
At close: Nov 14, 2025, 4:00 PM EST
691.50
-2.00 (-0.29%)
After-hours: Nov 14, 2025, 7:56 PM EST
Regeneron Pharmaceuticals Market Cap
Regeneron Pharmaceuticals has a market cap or net worth of $71.15 billion as of November 14, 2025. Its market cap has decreased by -30.05% in one year.
Market Cap
71.15B
Enterprise Value
55.13B
1-Year Change
-30.05%
Ranking
Category
Stock Price
$693.50
Market Cap Chart
Since December 1, 1998, Regeneron Pharmaceuticals's market cap has increased from $252.00M to $71.15B, an increase of 28,135.21%. That is a compound annual growth rate of 23.27%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 14, 2025 | 72.89B | -6.89% |
| Dec 31, 2024 | 78.28B | -18.19% |
| Dec 29, 2023 | 95.69B | 21.78% |
| Dec 30, 2022 | 78.57B | 15.69% |
| Dec 31, 2021 | 67.92B | 31.74% |
| Dec 31, 2020 | 51.55B | 25.04% |
| Dec 31, 2019 | 41.23B | 1.98% |
| Dec 31, 2018 | 40.43B | 0.08% |
| Dec 29, 2017 | 40.39B | 4.33% |
| Dec 30, 2016 | 38.72B | -31.47% |
| Dec 31, 2015 | 56.49B | 35.45% |
| Dec 31, 2014 | 41.71B | 52.42% |
| Dec 31, 2013 | 27.36B | 65.66% |
| Dec 31, 2012 | 16.52B | 221.91% |
| Dec 30, 2011 | 5.13B | 89.94% |
| Dec 31, 2010 | 2.70B | 38.80% |
| Dec 31, 2009 | 1.95B | 33.11% |
| Dec 31, 2008 | 1.46B | -8.46% |
| Dec 31, 2007 | 1.60B | 38.55% |
| Dec 29, 2006 | 1.15B | 29.12% |
| Dec 30, 2005 | 893.00M | 73.94% |
| Dec 31, 2004 | 513.40M | -36.89% |
| Dec 31, 2003 | 813.50M | -0.20% |
| Dec 31, 2002 | 815.10M | -33.81% |
| Dec 31, 2001 | 1.23B | -5.01% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 916.26B |
| Johnson & Johnson | 471.52B |
| AbbVie | 417.92B |
| UnitedHealth Group | 300.54B |
| AstraZeneca | 276.17B |
| Novartis AG | 256.16B |
| Merck & Co. | 231.92B |
| Abbott Laboratories | 224.56B |